BASINGSTOKE, England and PHILADELPHIA, July 19 /PRNewswire-FirstCall/ -- As previously disclosed, Shire plc will announce second quarter 2007 earnings on Thursday 26 July 2007.
However, due to the number of other companies also reporting results on that day, Shire has decided to change the time of its investor / analyst meeting to 30 minutes later than previously announced.
All other details remain the same. Results press release will be issued at: 12:00 BST / 07:00 EDT Investor meeting and conference call time: 14:30 BST / 09:30 EDT
Analyst meeting and conference call:
Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the investor and analyst meeting and conference call at 14:30 BST/9:30 EDT. The venue for the meeting will be at the offices of Financial Dynamics, Holborn Gate, 26 Southampton Buildings, London WC2A 1PB.
Please email claire.rowell@fd.com to register to attend the analyst meeting in London.
The details of the conference call are as follows: UK dial in: 0800-953-0810 US dial in: +1-866-789-2220 International dial in: +44-(0)1452-560-068 Password/Conf ID: 10176864# Live Webcast:(1) http://gaia.world-television.com/shire/20070726/
Replay:
A replay of the presentation will be available for two weeks by phone and by webcast for one year. Details are as follows:
UK dial in 0800-953-1533 US dial in +1-866-247-4222 International dial In: +44-(0)1452-55-00-00 Pin code 10176864# Webcast replay:(1) http://gaia.world-television.com/shire/20070726/ (1) Email verification is required For further information please contact: Investor Relations Souheil Salah (Rest of the World) +44-1256-894-160 Heidi Wunder (North America) +1-484-595-8970 Notes to editors SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company’s website: www.shire.com.
Shire PLC
CONTACT: Hampshire International Business Park, Chineham Basingstoke,Hampshire RG24 8EP, United Kingdom, Tel +44-(0)1256-894000, Fax+44-(0)1256-894708, www.shire.com
